## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG 1.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 2)

**1. Guidance Cut From Higher Exchange Costs Could Be A Game Changer For Centene (CNC)**
- Source: Simply Wall Street | 20251204T200857 | Bearish | Relevance: 100%
- Centene (CNC) has cut its earnings guidance due to higher-than-expected medical utilization in its federal exchange plans and ongoing pressure in its Medicaid business. This adjustment raises concerns that potential changes to federal exchange subsidy policy could lead to a smaller, sicker enrollee base, putting additional pressure on profitability and reshaping Centene's investment narrative. The company's updated 2025 outlook now anticipates a GAAP diluted loss per share not exceeding US$12.85, impacting its short-term earnings recovery prospects.

**2. Invesco Ltd. Purchases 633,946 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251204T120816 | Neutral | Relevance: 100%
- Invesco Ltd. increased its holdings in Centene Corporation by 5.7%, acquiring an additional 633,946 shares, bringing its total ownership to 11,725,910 shares valued at approximately $636.5 million. Centene reported strong Q3 earnings, beating analyst expectations with $0.50 EPS and $49.69 billion in revenue, showing an 18.2% year-over-year revenue increase. The company currently holds an average analyst "Hold" rating with a consensus target price of $40.00.

**3. Is Centene Stock Underperforming the S&P 500?**
- Source: Markets Financial Content | 20251204T073700 | Neutral | Relevance: 100%
- Centene Corporation (CNC) stock has dropped 41.9% from its 52-week high, underperforming the S&P 500 Index (SPX) on a YTD and 52-week basis, despite a recent 29.1% gain over the past three months and a significant jump after raising its 2025 adjusted profit forecast. Analysts maintain a "Hold" rating due to its weak performance.

**4. Centene director Burdick sells $2.57 million in stock**
- Source: Investing.com India | 20251205T224551 | Neutral | Relevance: 100%
- Centene director Kenneth A. Burdick recently sold 65,907 shares of common stock for approximately $2.57 million in two transactions. Despite this sale, Centene has a strong free cash flow yield of 18% and management is aggressively buying back shares. The company has also announced significant expansion of its Medicare Advantage plans and reported strong adjusted earnings per share for Q3 2025.

**5. Cresset Asset Management LLC Reduces Stock Holdings in Centene Corporation $CNC**
- Source: MarketBeat | 20251205T101145 | Neutral | Relevance: 100%
- Cresset Asset Management LLC decreased its stake in Centene Corporation by 17.5% in the second quarter, now holding 773,963 shares worth $42,011,000. Other hedge funds like Assetmark Inc. and GHP Investment Advisors Inc. also adjusted their positions, while Centene reported Q3 earnings of $0.50 EPS, surpassing consensus estimates. The stock has an average "Hold" rating from analysts with an average target price of $40.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 13.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.64 elevated, pricing in significant growth expectations. Forward P/E 13.3x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.64 |
| Forward P/E | 13.3 |
| Current P/E | 19.0 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 1.8% to 0.4% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 55. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.40% (CS: 58) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 0.863x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.34
- **Stop Loss:** $35.44 (7.6% risk)
- **Target:** $41.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 172
- **Position Value:** $6,594.48
- **Portfolio %:** 6.59%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*